These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36681988)

  • 1. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.
    Dohm AE; Tang JD; Mills MN; Liveringhouse CL; Sandoval ML; Perez BA; Robinson TJ; Creelan BC; Gray JE; Etame AB; Vogelbaum MA; Forsyth P; Yu HM; Oliver DE; Ahmed KA
    J Neurosurg; 2023 Jun; 138(6):1600-1607. PubMed ID: 36681988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study.
    Bodensohn R; Kolorz A; Reis J; Werner S; Forbrig R; Garny S; Taugner J; de Colle C; Belka C; Manapov F; von Baumgarten L; Niyazi M
    Transl Lung Cancer Res; 2024 Jul; 13(7):1635-1648. PubMed ID: 39118877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases.
    Chiou GY; Chiang CL; Yang HC; Shen CI; Wu HM; Chen YW; Chen CJ; Luo YH; Hu YS; Lin CJ; Chung WY; Shiau CY; Guo WY; Pan DH; Lee CC
    J Neurosurg; 2022 Aug; 137(2):563-570. PubMed ID: 34920439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiinstitutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases from non-small cell lung cancer (JLGK0901 study-NSCLC).
    Shuto T; Akabane A; Yamamoto M; Serizawa T; Higuchi Y; Sato Y; Kawagishi J; Yamanaka K; Jokura H; Yomo S; Nagano O; Aoyama H
    J Neurosurg; 2018 Dec; 129(Suppl1):86-94. PubMed ID: 30544291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
    Shepard MJ; Xu Z; Donahue J; Eluvathingal Muttikkal TJ; Cordeiro D; Hansen L; Mohammed N; Gentzler RD; Larner J; Fadul CE; Sheehan JP
    J Neurosurg; 2020 Sep; 133(3):685-692. PubMed ID: 31349225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI).
    Yomo S; Serizawa T; Yamamoto M; Higuchi Y; Sato Y; Shuto T; Akabane A; Jokura H; Kawagishi J; Aoyama H
    J Neurooncol; 2019 Oct; 145(1):151-157. PubMed ID: 31487030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post-stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2024 Aug; ():1-10. PubMed ID: 39178473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it advisable to perform radiosurgery for EGFR-TKI-controlled brain metastases? A retrospective study of the role of radiosurgery in lung cancer treatment.
    Hung JS; Su YH; Chen CJ; Chiang CL; Shen CI; Yang HC; Shiau CY; Luo YH; Wu HM; Hu YS; Lin CJ; Liu KD; Chung WY; Guo WY; Lee CC
    J Neurooncol; 2023 Sep; 164(2):413-422. PubMed ID: 37656378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.
    Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N
    Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases.
    Vaios EJ; Shenker RF; Hendrickson PG; Wan Z; Niedzwiecki D; Winter SF; Shih HA; Dietrich J; Wang C; Salama AKS; Clarke JM; Allen K; Sperduto P; Mullikin T; Kirkpatrick JP; Floyd SR; Reitman ZJ
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1507-1518. PubMed ID: 38097090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Jun; 138(6):1591-1599. PubMed ID: 36308485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
    Kuan AS; Chiang CL; Wu HM; Yang HC; Chen CJ; Lin CJ; Guo WY; Pan DH; Chung WY; Lee CC
    J Neurooncol; 2023 Sep; 164(3):729-739. PubMed ID: 37721662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010-2019 Retrospective Cohort Study.
    Tatineni V; O'Shea PJ; Saxena S; Khosla AA; Ozair A; Kotecha RR; Jia X; Rauf Y; Murphy ES; Chao ST; Suh JH; Peereboom DM; Ahluwalia MS
    Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37296975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
    Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
    World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.